Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Ramipril 1.25 mg tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
blister
Packaging
10*15
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Ramipil 1.25 Tablet contains Ramipril 1.25 mg, an ACE (Angiotensin-Converting Enzyme) inhibitor that helps manage high blood pressure and heart failure and reduces the risk of stroke and heart attack. It works by relaxing blood vessels, lowering blood pressure, and improving blood flow, thereby easing the strain on the heart. It is also used to delay the progression of kidney disease in diabetic patients with hypertension.
Most patients tolerate Ramipril well. However, some may experience dry cough, dizziness, headache, fatigue, or gastrointestinal discomfort. In rare cases, serious effects like angioedema, hypotension, or kidney function changes may occur. Regular monitoring is advised.
Ramipil 1.5 Tablet is indicated for the treatment of mild to moderate hypertension, congestive heart failure, post-myocardial infarction care, and cardiovascular event risk reduction in high-risk patients. It is also beneficial in slowing down the progression of kidney disorders in diabetic patients.
Use only under medical supervision. Not to be used during pregnancy or in patients with a history of angioedema related to ACE inhibitors. Monitor renal function and electrolytes during therapy. Do not stop the medication abruptly without a doctor’s advice.
Store at a temperature below 30°C, away from moisture and direct sunlight. Keep out of reach of children.
Composition : Prasugrel 10 mg Tablets
Composition : Ramipril 2.5 mg tablet
Composition : Ramipril 5 mg tablet
Composition : Ramipril (10mg) tablet
Composition : Nitroglycerine 2.6 mg Tablet
Composition : Nitroglycerine 6.4 mg Tablet
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Ramipril 1.25 mg Tablet is an ACE inhibitor antihypertensive medication used for the management of high blood pressure (hypertension), heart failure, and prevention of cardiovascular events in high-risk patients. It works by relaxing blood vessels, improving blood flow, and reducing strain on the heart, making it an important product in the cardiology and cardiovascular care segment, with strong demand in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand from cardiologists, physicians, and general practitioners. As hypertension and heart diseases require long-term therapy, Ramipril 1.25 mg ensures regular prescriptions, repeat orders, and stable market growth, making it a dependable product for cardiovascular portfolios.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and antihypertensive segment with monopoly rights, quality manufacturing standards, attractive promotional support, and reliable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from strong prescription demand, long-term patient adherence, increasing cardiovascular disease burden, and continuous institutional requirements, making this product a profitable and sustainable addition to their pharmaceutical business when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in cardiovascular and antihypertensive formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiac segment.